Article Text

Download PDFPDF

Benefit from adrenocorticotrophin in myasthenia gravis
  1. L. A. Liversedge,
  2. G. M. Yuill,
  3. I. M. S. Wilkinson,
  4. J. A. Hughes
  1. Department of Neurology, Royal Infirmary, Manchester


    Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course of injections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.